The influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis
Epidemiological evidence has established a central role of Epstein-Barr virus (EBV) in the pathogenesis of multiple sclerosis (MS). While EBV-specific T-cell responses may influence disease progression, the impact of anti-CD20 B-cell depletion therapy (BCDT) on EBV-specific cellular and humoral immunity remains insuffi...